NIAC recommends the immunisation of all adults aged 65 years and older with recombinant zoster vaccine (RZV). 


(a) NIAC recommends the immunisation of adults with immunocompromising conditions (Table 1) aged 50 years and older with RZV. 

(b) NIAC recommends the immunisation of HSCT recipients, aged 18 years and older, with RZV. 

(c) NIAC recommends that immunisation with RZV is considered for patients aged 18-49 years and older with immunocompromising conditions (Table 1) in particular solid organ transplant recipients, those with haematological malignancies and those with advanced oruntreated HIV (CD4 count <200 cells/μl), in consultation with their treating hospital specialist. 

3.For both immunocompetent and immunocompromised adults, RZV should be given as two doses (0.5ml) with a 2–6-month interval between doses.

**For subjects who are or might become immunodeficient or immunosuppressed due to disease or therapy, and who would benefit from a shorter vaccination schedule, the second dose can be given 1 to 2 months after the initial dose.



  • Recommendation
  • Europe
  • Ireland
  • Herpes zoster